Development and evaluation of novel itraconazole-loaded intravenous nanoparticles

International Journal of Pharmaceutics

Volumn 362, Issue 1-2, 2008, Pages 133-140

  Chen, Wei ^a   Gu, Bing ^a   Wang, Hao ^b   Pan, Jun ^a   Lu, Weiyue ^a   Hou, Huimin ^b  

^a FUDAN UNIVERSITY   (China)

^b National Pharmaceutical Engineering and Research Center   (China)

Author keywords

Itraconazole; Nanoparticle albumin bound technology; Pharmacokinetics; Tissue distribution

Indexed keywords

DRUG METABOLITE; HUMAN SERUM ALBUMIN; HYDROXYLITRACONAZOLE; ITRACONAZOLE; ITRACONAZOLE LOADED NANOPARTICLE; NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BIOCOMPATIBILITY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG LIVER LEVEL; DRUG SAFETY; DRUG STABILITY; DRUG TOLERABILITY; FEMALE; FREEZE DRYING; HEMOLYSIS; HOMOGENIZATION; LUNG; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NANOPARTICLE ALBUMIN BOUND TECHNOLOGY; NONHUMAN; PHARMACEUTICAL ENGINEERING; POWDER; PRIORITY JOURNAL; SPLEEN; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXICITY TESTING;

ANIMALS; CALORIMETRY, DIFFERENTIAL SCANNING; DRUG CARRIERS; DRUG EVALUATION, PRECLINICAL; DRUG STABILITY; FEMALE; INJECTIONS, INTRAVENOUS; ITRACONAZOLE; MALE; MICE; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PARTICLE SIZE; SERUM ALBUMIN; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; SURFACE PROPERTIES; TECHNOLOGY, PHARMACEUTICAL; TISSUE DISTRIBUTION; X-RAY DIFFRACTION;

EID: 50249163680     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.05.039     Document Type: Article

References (37)

1. Cheung R.Y., Kuba R., Rauth A.M., and Wu X.Y. A new approach to the in vivo and in vitro investigation of drug release from locoregionally delivered microspheres. J. Control. Release 100 (2004) 121-133
2. Cohen B.E. Amphotericin B toxicity and lethality: a tale of two channels. Int. J. Pharm. 162 (1998) 95-106
3. Desai, N.P., Tao, C., Yang, A., Louie, L., Zheng, T.L., et al., 1999. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof. U.S. Patent No. 5,916,596.
4. Dreis S., Rothweiler F., Michaelis M., Cinatl Jr. J., Kreuter J., and Langer K. Preparation, characterization and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles. Int. J. Pharm. 341 (2007) 207-214
5. Edwards J.E., Bodey G.P., Bowden R.A., Büchner T., de Pauw B.E., Filler S.G., Ghannoum M.A., Glauser M., Herbrecht R., Kaufmann C.A., Kohno S., Martino P., Meunier F., Mori T., Pfaller M.A., Rex J.H., Rogers T.R., Rubin R.H., Solomkin J.C., Viscoli C., Walsh T.J., and White M. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin. Infect. Dis. 25 (1997) 43-59
6. Esmaelli F., Ghahremani M.H., Esmaeili B., Esmaeili B., Khoshayand M.R., Atyabi F., and Dinarvand R. PLGA nanoparticles of different surface properties: preparation and evaluation of their body distribution. Int. J. Pharm. 349 (2008) 249-255
7. Furumoto K., Yokoe J., Ogawara K., Amano S., Takaguchi M., Higaki K., Kai T., and Kimura T. Effect of coupling of albumin onto surface of PEG liposome on its in vivo disposition. Int. J. Pharm. 329 (2007) 110-116
8. Grant S., and Clissold S. Itraconazole: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in superficial and systemic mycoses. Drug 37 (1989) 310-344
9. Gref R., Minamitake Y., Peracchia M.T., Tubetskoy V., Torchilin V., and Langer R. Biodegradable long-circulating polymeric nanospheres. Science 263 (1994) 1600-1603
10. Grislain L., Couvreur P., Lenaerts V., Roland M., Deprez-Decampeneere D., and Speiser P. Pharmacokinetics and distribution of a biodegradable drug-carrier. Int. J. Pharm. 15 (1983) 335-345
11. Groll A.H., Wood L., Roden M., Mickiene D., Chiou C.C., Townley E., Dad L., Piscitelli S.C., and Walsh T.J. Safety, pharmacokinetics and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. Antimicrob. Agents Chemother. 46 (2002) 2554-2563
12. Heykants J., Michiels M., Meuldermans W., Monbaliu J., Lavrijsen K., Van Peer A., Levron J.C., Woestenborghs R., and Cauwenbergh G. The pharmacokinetics of itraconazole in animals and man: an overview. In: Fromtling R.A. (Ed). Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents (1987), J.R. Prous Science Publishers, Barcelona, Spain 57-83
13. Hong J.Y., Kim J.K., Song Y.K., Park J.S., and Kim C.K. A new self-emulsifying formulation of itraconazole with improved dissolution and oral absorption. J. Control. Release 110 (2006) 332-338
14. Li F.Q., Su H., Wang J., Liu J.Y., Zhu Q.G., Fei Y.B., Pan Y.H., and Hu J.H. Preparation and characterization of sodium ferulate entrapped bovine serum albumin nanoparticles for liver targeting. Int. J. Pharm. 349 (2008) 274-282
15. Lortholary O., Denning D.W., and Dupont B. Endemic mycoses: a treatment update. J. Antimicrob. Chemother. 43 (1999) 321-331
16. Matteucci M.E., Hotze M.A., Johunston K.P., and Williams R.O. Drug nanoparticles by antisolvent precipitation: mixing energy versus surfactant stabilization. Langmuir 22 (2006) 8951-8959
17. Mikami Y., Sakamoto T., Yazawa K., Gonoi T., Ueno Y., and Hasegawa S. Discrepancies in bioassay and chromatography determinations explained by metabolism of itraconazole to hydroxyitraconazole: studies of interpatient variations in concentrations. Antimicrob. Agents Chemother. 37 (1994) 2224-2227
18. Odds F.C., and Bossche H.V. Antifungal activity of itraconazole compared with hydroxy-itraconazole in vitro. J. Antimicrob. Chemother. 45 (2000) 371-373
19. Ogawara K., Yoshida M., Higaki K., Kimura T., Shiraishi K., Nishikawa M., Takakura Y., and Hashida M. Hepatic uptake of polystyrene microspheres in rats: effect of particle size on intrahepatic distribution. J. Control. Release 59 (1999) 15-22
20. Peeters J., Neeskens P., Tollenaere J.P., Van P., and Brewster M. Characterization of the interaction of 2-hydroxy-β-cyclodextrin with itraconazole at pH 2, 4 and 7. J. Pharm. Sci. 91 (2002) 1414-1422
21. Phillips P., De Beule K., Frechette G., Tchamouroff S., Vandercam B., Weitner L., Hoepelman A., Stingl G., and Clotet B. A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS. Clin. Infect. Dis. 26 (1998) 1368-1373
22. Picardi M., Camera A., Luciano L., Ciancia R., and Rotoli B. Intravenous itraconazole for treating invasive pulmonary aspergillosis in neutropenic patients with acute lymphoblastic leukemia. Haematologica 88 (2003) ELT01
23. 3 factorial design. AAPS PharmSciTech. 4 (2003) 565-573
24. Rabinow B., Kipp J., Papadopoulos P., Wong J., Glosson J., Gass J., Sun C.S., Wielgos T., White R., Cook C., Barker K., and Wood K. Itraconazole IV nanosuspension enhances efficacy through altered pharmacokinetics in the rat. Int. J. Pharm. 339 (2007) 251-260
25. Rajewski R.A., and Stella V.J. Pharmaceutical applications of cyclodextrins. 2. in vivo drug delivery. J. Pharm. Sci. 85 (1996) 1142-1169
26. Revankar S., Kirkpatrick W., McAtee R., Dib O., Fothergill A., Redding S., Rinaldi M., and Patterson T. Detection and significance of fluconazole resistance in orpharyngeal candidiasis in human immunodeficiency virus infected patients. J. Infect. Dis. 174 (1996) 821-827
27. Rex J., Pfaller M., Galgiani J., Bartlett M., Espinel-Ingroff A., Ghannoum M., Lancaster M., Odds F., Rinaldi M., Walsh T., and Barry A. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24 (1997) 235-247
28. Sheehan D.J., Hitchcock C.A., and Sibley C.M. Current and emerging azole antifungal agents. Clin. Microbiol. Rev. 12 (1999) 40-79
29. Singh N., and Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J. Heart Lung Transplant. 22 (2003) 258-266
30. Thomson, P.D.R., Montvale, N.J., 2005. Physician's Desk Reference, 59th, pp. 1757-1766.
31. Van Cauteren H., Heykants J., De Coster R., and Cauwenbergh G. Itraconazole: pharmacologic studies in animals and humans. Rev. Infect. Dis. 9 (1987) S43-S46
32. Walsh T.J., Teppler H., Donowitz G.R., Maertens J.A., Baden L.R., Dmoszynska A., Cornely O.A., Bourque M.R., Lupinacci R.J., Sable C.A., and dePauw B.E. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neiutropenia. N. Engl. J. Med. 351 (2004) 1391-1402
33. Wartlick H., Spänkuch-Schmitt B., Strebhardt K., Kreuter J., and Langer K. Tumour cell delivery of antisense oligonuclceotides by human serum albumin nanoparticles. J. Control. Release 96 (2004) 483-495
34. Weber C., Kreuter J., and Langer K. Desolvation process and surface characteristics of HSA-nanoparticles. Int. J. Pharm. 196 (2000) 197-200
35. Wong J.W., Nisar U.R., and Yuen K.H. Liquid chromatographic method for the determination of plasma itraconazole and its hydroxyl metabolite in pharmacokinetic/bioavailability studies. J. Chromatogr. B 798 (2003) 335-360
36. Yamashita C., Matsuo H., Akiyama K., and Kiwada H. Enhancing effect of cetylmannoside on targeting of liposomes to Kupffer cells in rats. Int. J. Pharm. 70 (1991) 225-233
37. Yi Y., Yoon H.J., Kim B.O., Shim M., Kim S.O., Hwang S.J., and Seo M.H. A mixed polymeric micellar formulation of itraconazole: characteristics, toxicity and pharmacokinetics. J. Control. Release 117 (2007) 59-67